Peningkatan Kadar Lipoprotein-Associated Phospholipase A2 Meningkatkan Kejadian Stroke Iskemik Akut
Abstract
Introduction: Stroke is a major health problem in the world, and associated with mortality, disability, and economic burden. Stroke is the second leading cause of death in the world after heart disease and cause of disability in adults. Several recent studies show that levels of Lp-PLA2 contribute to high serum lead to ischemic stroke, whereas some others do not get the association. Aims: studies an association between serum Lp-PLA2 with incident ischemic stroke. Method: This study is a descriptive analytic comparative with cross sectional design in the Neurology ward RS. DR. M. Djamil Padang between October 2013 to April 2014 with total of 88 subjects consisting of 44 subjects ischemic stroke patients and 44 healthy control group who participated in the study. Statistical analysis is used parametric test with unpaired t test, test for normality with the Kolmogorov-Smirnov test, and logistic regression analysis. Result: P value 0.05 was considered statistically significant. The mean age of subjects in the group of ischemic stroke patients was 57.30 ±8.86 years old. Female in patients with ischemic stroke group was 23 people (52,3%). Mean levels of Lp-PLA2 serum in patiens with ischemic stroke group was 103.49±48.00 ng/mL. A significan association between serum levels of Lp-PLA2 with incident ischemic stroke with p<0.05. Conclusion: There was a significant relation in elevation of serum Lp-PLA2 levels with incident of ischemic stroke.
Keywords
Full Text:
PDFReferences
Zhou F, Liu Y, Shi H, Huang Q, Zhou J. Relation between lipoprotein-associated phospholipase A2 mass and incident ischemic stroke severity.Springer Neurological Science. 2018
Huang Fubao, Wang K, Shen J. 2019.Lipoprotein‐associated phospholipase A2:The story continues. Wiley Online Library
Li D, Wei W, et al. 2017.Lipoprotein-associated phospholipase A2 and risks of coronary heart disease and ischemic stroke in the general population: A systematic review and meta-analysis. Elsevier
Monbailliu T, Gossens J,Hachimi-Idrissi S. 2017.Blood protein biomarkers as diagnostic tool for ischemic stroke: a systematic review.Biomarkers in Medicine.
Bejot Y, Bailly H, Durier J,Giroud M. 2016.Epidemiology of stroke in Europe and trends for the 21st century. Presse Med
Garg P K, Norby F L, et al. 2018. Lipoprotein-associated phospholipase A2 and risk of incident peripheral arterial disease: Findings from The Atherosclerosis Risk in Communities study (ARIC).Elsevier
Hu G, Liu D, Tong H, Huang W, Hu Y, Huang Y. 2019.Lipoprotein-Associated Phospholipase A2 Activity and Mass as Independent Risk Factor of Stroke: A Meta-Analysis. BioMed Research International
Tian Y, Jia H, Li S, Wu Y, Guo L,Tan G, Li B..The associations of stroke, transient ischemic attack, and/or stroke-related recurrent vascular events with Lipoprotein-associated phospholipase A2 : A systematic review and meta-analysis.Medicine.2017
Dhamoon M S, Cheung Y K, Moon Y P, Wright Y B, Sacco R L, Elkind M S V. 2019. Interleukin-6 and lipoprotein-associated phospholipase A2 are associated with functional trajectories.PLOSONE
Khoshnam S E,Winlow W, Farzaneh M.2017.The Interplay of MicroRNAs in the Inflammatory Mechanisms Following Ischemic Stroke. American Association of Neurophatologist.
Rasyid A, Harris S, Kurniawan M, Mesiano T. Buku Ajar Neurologi: Stroke Iskemik. Fakultas Kedokteran Universitan Indonesia; 2017
Caplan,L.R Caplan Stroke :A Clinical Approach.4th ed. United State of Amerika : Saunder Elsevier. 2009
Katan M, Moon Y P, Paik M C, Wolfert R L, Sacco R L, Elkind M S V. 2014. Lipoprotein-Associated Phospholipase A2 Is Associated with Atherosclerotic Stroke Risk: The Northern Manhattan Study
Wang Y, Hu S, Ren L, Lei Z., Lan T, Cai J, Li C. 2018. Lp-PLA2 as a risk factor of early neurological deterioration in acute ischemic stroke with TOAST type of large arterial atherosclerosis
Lin J, Zheng H, Cucchiara BL, et al. Association of Lp-PLA2-A and early recurrence of vascular events after TIA and minor stroke. Neurology. 2015
Benjamin EJ, Virani SS, Callaway CW, et al. Heart Disease and Stroke Statistics‐2018 update: a report from the American Heart Association. Circulation. 2018
Benderly M, Sapir B, Kalter-Leibovici O, et al. Lipoprotein-associated phospholipase A2, and subsequent cardiovascular events and mortality among patients with coronary heart disease. Biomarkers. 2017
Wei L, Ke Z, Zhao Y, et al. The elevated lipoproteinassociated phospholipase A2 activity is associated with the occurrence and recurrence of acute cerebral infarction. Neuroreport. 2017
Ueshima H, Kadowaki T, Hisamatsu T, et al. Lipoprotein‐associated phospholipase A2 is related to risk of subclinical atherosclerosis but is not supported by Mendelian randomization analysis in a general Japanese population. Atherosclerosis. 2016
Gregson JM, Freitag DF, Surendran P, et al. Genetic invalidation of Lp‐PLA2 as a therapeutic target: large‐scale study of five functional Lp‐PLA2‐lowering alleles. Eur J Preventive Cardiol. 2017
DOI: https://doi.org/10.33854/heme.v3i1.485
Refbacks
- There are currently no refbacks.
Health and Medical Journal This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.